ClinicalTrials.gg
RecruitingNCT05445063Updated Jul 6, 2022

Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

A Phase 1 interventional study of Autologous iPSC-derived RPE in Macular Degeneration, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Beijing Tongren Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
85th of 91
10 · median 62
Started
2022
with 6 others
Phase 1
20 of 107
5 open now
Primary completion
2026-07
later than 17 of 42 live
Registered
54th of 107
by date

Among the 107 studies in Macular Degeneration with a site in China, this one is the 85th largest by planned enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2022, is one of 20 in phase 1, reaches primary completion later than 17 of the 42 other live ones, and was the 54th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 107 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE). The clinical-grade RPE will be transplanted into subretinal space to treat refractory age-related macular degeneration. The efficacy and safety of RPE transplants to treat macular degeneration will be monitored and analyzed with results from EDTRS, BCVA, OCT, ERG, microperimetry, and fluorescein angiography, before and after the treatment.

Read the detailed description

The investigators will generate iPSC lines from recruited participants and differentiate the iPSC into RPE. Autologous iPSC-derived RPE will be transplanted into participants eyes by subretinal injections. The safety and efficacy will be closely monitored and analyzed.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Retinal disease
  • Macular degeneration
  • Stem Cells
  • RPE
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 50-75 years;
  • Clinical diagnosis is consistent with the definition of late dry AMD in the age-related eye disease study (AREDS), with one or more >250 um geographic atrophy in the fovea;
  • Clinical diagnosis is wet AMD, but no obvious efficacy after conventional treatment;
  • The BCVA of the target eye will be 0.05 to 0.3;
  • Voluntary as test subjects, , regular follow-up on time.

Exclusion criteria

Exclusion Criteria:

  • One-eyed subjects;
  • Macular atrophy caused by other diseases in addition to AMD;
  • Suffer from retinitis pigmentosa, choroidal retinitis, central serous choroiditis, diabetic retinopathy, or other retinal vascular and degenerative diseases besides AMD;
  • Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, optic neuropathy, and other ocular histories;
  • Other intraocular surgery histories besides cataract surgery;
  • Combined with severe systemic diseases, such as heart failure, liver disease, renal insufficiency, cor pulmonale, in the previous 12 months;
  • Combined with severe infectious diseases, such as , , , syphilis, tuberculosis, etc;
  • Abnormal blood coagulation function or other laboratory tests;
  • If female and of , pregnant, breastfeeding, or planning to become pregnant through the study;
  • If male, refuse to use barrier and spermicide during the study;
  • Malignant tumor and history of ;
  • Any immune deficiency;
  • Allergy to tacrolimus or other macrolides;
  • Any immune deficiency;
  • Use , drugs, or antipsychotic drugs in the previous 3 months;
  • Use anticoagulant, or the function is still not restored to normal after stopping antiplatelet drugs for 10 days;
  • A history of addiction to alcoholism or prohibited drugs;
  • Be participating in other intervention clinical trials or receiving other study medications;
  • Poor compliance, difficulty to complete the study, or refusal to ;
  • Some other situations which might increase the risks of the subjects or interfere with clinical trials, such as mental disorders, cognitive dysfunction, etc.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Participants receiving intervention

    Participants will receive autologous transplantation of induced pluripotent stem cell-derived retinal pigment epitheliums.

    Biological: Autologous iPSC-derived RPE

Interventions

  • BiologicalAutologous iPSC-derived RPE

    Autologous transplantation of iPSC-derived RPE

06

What researchers measure

Primary outcomes

  1. Safety measure

    Safety will be assessed by Adverse Events (AEs) of special interest in regards to the investigational product. This will include obtaining information about Serious Adverse Events (SAEs) that are neurologic, infectious, hematologic or fatal, any AE that causes the subject to withdraw from the study, any new diagnosis of an ocular or immune-mediated disorder, cancer (irrespective of prior history), ectopic or proliferative cell growth (RPE or non-RPE) with adverse clinical consequence, unexpected, clinically significant AE possibly related to the cell transplant procedure or the investigational product (autologous iPSC-RPE), pregnancy in a female subject or the partner of a male subject and pregnancy outcome.

    Time frame: 12 months

Secondary outcomes

  1. Best Corrected Visual Acuity (BCVA)

    Change in visual acuity will be measured by Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

    Time frame: 12 months

  2. Optical coherence tomography (OCT) imaging

    The number of patients with serious retinal detachment, retinal hemorrhage, and cystoid macular edema, and the change in target treatment areas.

    Time frame: 12 months

  3. Color and autofluorescence imaging

    Change in target treatment areas.

    Time frame: 12 months

  4. Fluorescein angiography

    Change in target treatment areas.

    Time frame: 12 months

  5. Fundus autofluorescence

    Change in target treatment areas.

    Time frame: 12 months

  6. Microperimetry

    Exploratory evaluations for the change of retinal sensitivity from baseline in the region of interest.

    Time frame: 12 months

  7. Electroretinography (ERG)

    Exploratory evaluations for the change of retinal electrophysiology responses from baseline.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Beijing Tongren Hospitol,Capital Medical University
    Beijing, Beijing 100730, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Detailed plan will be made based on institute regulations and funder policies. The investigators will adjust the plan case-by-case accordingly.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2022; primary completion for Jul 2026, 47 months later.

Of 75 phase 1 interventional studies under Macular Degeneration, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 30. This study's planned 47 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2022
First posted
Jul 6, 2022
StartEst.
Aug 2022
Primary completionEst.
Jul 2026
CompletionEst.
Dec 2026
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05445063
Responsible party
Sponsor
First posted
Jul 6, 2022
Start date
Aug 2022 (estimated)
Primary completion
Jul 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 6, 2022

Study contacts

Xiaohui Zhang
Contact
zhangxh711@126.com
+0086-(010)58265915

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion